A long way to the battlefront: CAR T cell therapy against solid cancers

Chimeric antigen receptors (CARs) are engineered synthetic receptors that redirect and reprogram T cells to tumor surface antigens for subsequent eradication. The unprecedented efficacy of CD19-CAR T cells against B-cell malignancies has inspired oncologists to extend these efforts for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhicai, Chen, Wei, Zhang, Xing, Cai, Zhiming, Huang, Weiren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603378/
https://www.ncbi.nlm.nih.gov/pubmed/31289581
http://dx.doi.org/10.7150/jca.30406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603378/
https://www.ncbi.nlm.nih.gov/pubmed/31289581
http://dx.doi.org/10.7150/jca.30406

Ejemplares similares